Terveystalo Oyj (HLSE:TTALO) has put fresh numbers on the table for Q2 2026, reporting revenue of €293.3 million and basic EPS of €0.11. Trailing twelve month revenue is about €1.21 billion and EPS is €0.54, framing the broader earnings picture. Over the past year, the company has seen quarterly revenue range from €280.4 million to €346.9 million and basic EPS move between €0.11 and €0.26, giving investors a clear view of how the top and bottom lines have tracked into the latest quarter. With a trailing net profit margin of 6.2%, this set of results keeps the focus firmly on how efficiently Terveystalo converts its healthcare revenue into sustainable profits.
See our full analysis for Terveystalo Oyj.With the headline numbers in place, the next step is to see how Terveystalo’s recent results line up with the widely followed narratives on growth, profitability, and risk that have been building around the stock.
See what the community is saying about Terveystalo Oyj
Margins, EPS and net income stay tightly grouped
- Across the last five quarters, Terveystalo Oyj’s quarterly net income has sat between €13.8 million and €33.4 million, with EPS between €0.11 and €0.26, so Q2 2026 net income of €13.8 million and EPS of €0.11 land at the lower end of that recent range.
- Consensus narrative expects earnings to reach €115.7 million with margins rising from 6.2% to 8.3%. However, the latest trailing twelve month net income is €67.9 million on €1.21 billion of revenue, so investors can compare that target against the current 6.2% margin and relatively tight EPS band across recent quarters.
- Analysts’ consensus view points to 4.0% annual revenue growth, while the last twelve months show €1.21 billion of revenue compared with quarterly figures clustered between €280.4 million and €346.9 million.
- The same consensus expects EPS of €0.85 by 2029, against the current trailing EPS of €0.54, which makes the recent €0.11 to €0.26 quarterly range a useful reference for how much earnings would need to scale.
Valuation gap versus DCF and €9.20 target
- At a share price of €7.32, Terveystalo is trading below the cited DCF fair value of €17.61 and also below the €9.20 analyst price target. Its trailing P/E of 12.2x sits under the European healthcare industry at 20.7x and the 17.2x peer average.
- Bulls point to this combination of lower P/E and gap to both DCF fair value and the €9.20 target as evidence that the market is not fully crediting the forecast earnings path. Yet the current trailing twelve month earnings of €67.9 million on €1.21 billion of revenue and a 6.2% margin show exactly what the present business is delivering today.
- Bullish expectations for roughly 8.7% to 8.75% annual earnings growth are being compared against a five year pattern where earnings grew about 1% per year and the most recent one year comparison showed weaker earnings, which is a clear stretch from history.
- Supporters also highlight that the company’s trailing earnings are described as high quality, which some investors may weigh alongside the discount to DCF fair value and the €9.20 target when judging whether the current P/E leaves room for re rating.
Debt load and 8.74% dividend coverage risk
- The risk summary flags a high level of debt alongside a trailing dividend yield of about 8.74% that is not covered by earnings, set against trailing twelve month net income of €67.9 million and a 6.2% net margin.
- Bears focus on the combination of this leverage and uncovered dividend, arguing that if revenue growth follows the ~2.8% annual forecast and stays below the cited 4.6% Finnish market rate, cash flows from €1.21 billion of trailing revenue may be stretched between servicing debt and maintaining the payout.
- Critics highlight that recent one year earnings were weaker versus the prior comparison, while revenue forecasts lag the broader market, so higher margins alone may need to carry a lot of the load if the 8.74% yield is to remain intact.
- On the other hand, the small lift in net margin from 6.1% to 6.2% and the high quality label on trailing earnings give bears a concrete baseline to watch for any pressure from interest costs or a potential change in dividend policy.
Next Steps
To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Terveystalo Oyj on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.
If the mix of upbeat and cautious views around Terveystalo Oyj leaves you uncertain, consider taking action while the details are fresh and test the numbers yourself with 3 key rewards and 2 important warning signs
See What Else Is Out There Beyond Terveystalo Oyj
Terveystalo Oyj is working with a relatively tight EPS range, a modest 6.2% net margin and a high, uncovered 8.74% dividend set against meaningful debt.
If that mix of leverage and dividend pressure feels uncomfortable, check out solid balance sheet and fundamentals stocks screener (416 results) today to quickly focus on companies where earnings and balance sheets work harder for you.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com